Helius Medical Q2 revenue $182K (down 29% YoY); secures first insurance reimbursement for PoNS at $23,900

Solana Co

2024-Q2 EPS reported -$2.48 revenue$317,000

Revenue $182K vs $256K YoY due to PTAP termination; up 35% sequentially from Q1 2024.
Net loss $1.6M flat YoY; EPS -$0.64 vs -$2.92; cash $6.4M, no debt, runway into 2025.
First third-party insurance reimbursement secured at $23,900 for PoNS; CMS final rate due Oct 1.
Completed enrollment in stroke registrational program; FDA submission targeted H1 2025.
VA and DoD contract prices set at ~$23,800/$7,300 for device/mouthpiece; VA sales build underway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.